Obesity, Fitness & Wellness Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity, Fitness & Wellness Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis Therapy
Studies from California Pacific Medical Center describe new findings in amyotrophic lateral sclerosis therapy
December 30th, 2006
New research, "AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis," is the subject of a report. "Effective treatment for amyotrophic lateral sclerosis (ALS) remains elusive. Motor neuron degeneration is the primary pathology in ALS; however non-neuronal cells contribute to the disease process," scientists in the United States report. "In particular, inflammatory processes have been shown to play an important role. AM1241 is a cannabinoid CB2 receptor selective agonist that has been shown to be effective in models of inflammation and hyperalgesia. Here we report that treatment with AM1241...
Source: Obesity, Fitness & Wellness Week (2006-12-30)
|
